KCM
ENGN icon

Kennedy Capital Management’s enGene Therapeutics ENGN Stock Holding History

Kennedy Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.9M Buy
425,781
+349,016
+455% +$3.11M 0.06% 375
2025
Q4 		$693K Buy
+76,765
New +$615K 0.01% 504

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Kennedy Capital Management's ENGN Position: Q1 2026 in Review

Kennedy Capital Management increased its enGene Therapeutics (ENGN) stake by 455% in Q1 2026, buying an estimated $3.11M and bringing the position to 425,781 shares worth $2.9M. The position accounts for 0.06% of the portfolio, ranked #375.

Kennedy Capital Management first reported a position in ENGN in Q4 2025 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Kennedy Capital Management held 425,781 shares of enGene Therapeutics worth $2.9M as of Q1 2026.
  • Kennedy Capital Management bought 349,016 enGene Therapeutics shares in Q1 2026, an estimated $3.11M.
  • enGene Therapeutics made up 0.06% of Kennedy Capital Management's portfolio in Q1 2026, its #375 holding.
  • Kennedy Capital Management first reported a position in enGene Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.